

# PeploBio & Biocode Partner to Launch First Validated Microclot Assay for Translational and Clinical Applications

*First validated Flow Cytometry based Microclot assay enables pharmaceutical teams to integrate microclot biomarkers into translational pipelines*


LONDON, UNITED KINGDOM,  
September 10, 2025 /

[EINPresswire.com/](https://www.einpresswire.com/) -- PeploBio Ltd. and Biocode Technologies today announced a strategic partnership to commercialize Microclot, the world's first validated fibrinoid microclot assay for pharmaceutical development and clinical diagnostics in chronic inflammatory diseases.

The collaboration combines Biocode's pioneering research—led by Professor Resia Pretorius, who first identified microclots' role in Long COVID, ME/CFS, and other chronic inflammatory conditions—with PeploBio's clinical delivery expertise as a translational contract research organization.

Dr. Nico Lambri, Chief Scientific Officer at PeploBio, said "Microclots represent a paradigm shift in how we understand and measure chronic inflammatory diseases. This partnership enables translational and clinical teams to quantify a previously invisible pathology and act on it."

Fibrinoid microclots are amyloid-like, fibrin-based clots that resist breakdown and remain undetectable by traditional markers such as D-dimer or CRP. Persistent microclot presence has been linked to hallmark symptoms including fatigue, breathlessness, cognitive dysfunction, and vascular impairment across multiple inflammatory conditions.



The graphic features the Biocode logo at the top left and the PeptoBio logo at the bottom right. The central text reads "Microclot Assay" in a large, bold font, followed by "The Validated Assay For Detecting & Quantifying Fibrinoid MicroCLOTS in...". Below this, four purple buttons with white checkmarks list the conditions: "Long COVID (PASC)", "ME/CFS", "Vascular Inflammation", and "Autoimmune Disorders". A central call to action says "Let's Advance Your Research Together". The background includes a network diagram of purple nodes and lines, and a circular inset showing a 3D model of a red blood cell with a yellow fibrin mesh (microclot) attached to its surface.

**biocode**

## Microclot Assay

The Validated Assay For Detecting & Quantifying Fibrinoid MicroCLOTS in...

- ✓ Long COVID (PASC)
- ✓ ME/CFS
- ✓ Vascular Inflammation
- ✓ Autoimmune Disorders

Let's Advance Your Research Together

**PeploBio**

The validated Microclot Assay enables pharmaceutical teams to detect and quantify fibrinoid microclots in chronic inflammatory diseases

The Microclot Assay delivers validated detection and quantification of microclots via flow cytometry, with reproducibility and scalability designed for pharmaceutical pipelines. The platform offers compatibility with clinical trial workflows, biobanked samples, and patient stratification studies.

“This assay transforms microclot detection from an academic concept into a practical tool for drug development,” said Este Marie Burger, CEO of Biocode Technologies. “It enables pharmaceutical and clinical research partners to seamlessly integrate microclot measurement into translational studies, supporting biomarker validation, patient stratification, and the advancement of clinical trial endpoints.”

The Microclot Assay is now available through PeploBio as a testing service, supporting biomarker validation and pharmacodynamic studies, stratified patient selection for clinical trials, pre- and post-intervention monitoring, and evaluation of vascular pathology in complex conditions. PeploBio offers custom study design, sample collection kits, and regulatory documentation to support both exploratory research and GCP-compliant programs.

#### About the Companies:

PeploBio is a Contract Research Organization specializing in the development, validation, and delivery of diagnostic and translational assays. With operations in the UK, USA, and Cyprus. PeploBio partners with biotech and pharmaceutical companies across immune monitoring, biomarker strategy, and regulatory compliance landscapes.

Biocode Technologies is an academic-led diagnostic innovation company dedicated to translating advanced research into scalable tools for clinical and translational use. The company is globally recognized for its pioneering work on microclots and chronic inflammatory disease pathology.

#### Media Contacts:

Dr. Nico Lambri, Chief Scientific Officer, PeploBio - Email: [nico@peplobio.com](mailto:nico@peplobio.com)

Aimee Tremaine, VP of Business Development, PeploBio - Email: [atremaine@peplobio.com](mailto:atremaine@peplobio.com)

Dr Nico Lambri

PeploBio Ltd

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/847514058>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.